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Abstract 
Objective:  Prehospital use of antiplatelet agents has been associated with an increased 
risk for ICH as well as a secondary increase in ICH volume after the initial hemorrhage.  
Strategies to reestablish platelet aggregation are used in clinical practice, but without any 
established guidelines or recommendations.  This article serves to evaluate the literature 
regarding “reversal” of antiplatelet agents in neurosurgical populations. 
Methods:  PUBMED and MEDLINE databases were searched for publications from 1966 
to 2009 relating to intracranial hemorrhage and antiplatelet agents.  The reference 
sections of recent articles, guidelines and reviews were reviewed and pertinent articles 
identified.  Studies were classified by two broad subsets; those describing intracranial 
hemorrhage relatable to a traumatic mechanism and those with a spontaneous intracranial 
hemorrhage.  Two independent auditors recorded and analyzed study design and the 
reported outcome measures.     
Results:  For the spontaneous intracranial hemorrhage group, 9 reports assessing 
antiplatelet effects on various outcome measures were identified.  Eleven studies 
evaluating the use of prehospital antiplatlets prior to a traumatic intracranial hemorrhage 
were examined.    
Conclusion:  The data assessing the relationship between outcome and prehospital 
antiplatelet agents in the setting of ICH is conflicting in both the trauma and the stroke 
literature.  Only one retrospective review specifically addressed outcomes after attempted 
reversal with platelet transfusion.  Further study is needed to determine whether platelet 
transfusion ameliorates hematoma enlargement and/or improves outcome in the setting of 
acute ICH. 
 
Keywords:  coagulopathy, antiplatelet agent, intracranial hemorrhage, aspirin, 
clopidogrel, trauma, stroke, platelet transfusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Introduction 
 Prophylactic treatment with anticoagulants and antiplatelet agents has clear 
benefits in select patients with cardiac and vascular diseases[1, 2].  Over the previous 
decade, there has been a significant increase in the use of these agents for primary 
prevention of stroke and heart disease and for prophylaxis and after percutaneous cardiac 
interventions.  Patients experiencing intracranial hemorrhage (ICH) while fully 
anticoagulated have been reported to present with larger hematoma volumes and suffer a 
worse prognosis compared to control groups with normal coagulation profiles[3-5].  
Further study has demonstrated that ICH progression in anticoagulated patients could be 
halted, and mortality significantly reduced, with a prompt reversal of anticoagulation[6].  
Some investigators have also reported that a prehospital antiplatelet regimen may be 
associated with hematoma expansion, an increased mortality rate, and a poor functional 
outcome[7-10].  As such, many institutions have established protocols to “reverse” the 
impairment of platelet aggregation caused by antiplatelet agents in patients presenting 
with ICH. 
 Several antiplatelet agents are commonly used in the outpatient setting.  Aspirin is 
widely used for a variety of indications including risk reduction from transient ischemic 
attacks, prevention of primary myocardial infarction, and prevention of colorectal 
cancer[11].  Aspirin irreversibly binds to the cyclooxygenase-1 (COX-1) enzyme and 
subsequently inhibits production of thromboxane A2, a potent eicosanoid involved in 
platelet aggregation[12].  Non-steroidal anti-inflammatory drugs (NSAIDs) are typically 
used for relief from arthritis and headache pain.  This class of medications acts upon on 
COX-1 in a reversible, dose-dependent inhibition; as the drug concentration decreases, 
COX-1 regains its enzymatic activity.  Aspirin differs from NSAIDs functionally in that 
aspirin-induced COX-1 inhibition is irreversible, secondary to protein acetylation[13].  
Clopidogrel and ticlopidine both selectively and irreversibly inhibit the P2Y12 ADP 
receptor.  These agents have been used effectively to treat a wide range of cardiovascular 
and cerebrovascular diseases, such as for prophylaxis after coronary or intracranial stent 
placement.  Due to an active metabolite, clopidogrel in particular persists after cessation 
of the medication.  Some studies have demonstrated a higher incidence of post-operative 
bleeding with clopidogrel as compared to aspirin, prompting some experts to recommend 
aggressive anti-platelet reversal for up to 4 days after the last known dose[14].  
This review will focus on the treatment of ICH in patients taking prehospital 
NSAIDS, aspirin and clopidogrel (Plavix), and ticlopidine (Ticlid).  Given the 
heterogeneity of the etiology of intracranial hemorrhages, spontaneous ICH and traumatic 
hemorrhages will be reviewed separately.  The pertinent literature is evaluated and 
reviewed for evidence-based recommendations or guidelines to provide treatment 
guidance to clinicians for patients presenting with antiplatelet associated intracranial 
hemorrhages.  
Methods 
Literature Review 
 PUBMED and MEDLINE databases were searched for publications from 1966 to 
the present using MeSH terms ‘antiplatelet’, ‘aspirin’, ‘clopidogrel (Plavix)’, ‘ticlopidine 
(Ticlid)’, ‘intracranial hemorrhage’, ‘head injury’, ‘traumatic hemorrhage’, ‘subdural 
hematoma’, and ‘stroke’.  The search was limited to articles in the English language and 
those relating to human subjects over the age of 18.  Reference sections of recent articles, 
guidelines and reviews were reviewed and pertinent articles identified.  Initially, articles 
identified as relevant were retrieved in abstract format.  Full-text manuscripts were 
subsequently obtained for all original articles applicable to the current review.  
 Two authors independently evaluated all selected articles (PC, AS). For each 
study, study design (prospective or retrospective, use of control group, randomization), 
number of patients included and outcomes of the study were recorded.  These results 
were used to assess if any evidence-based recommendations were able to be made from 
the literature. 
Spontaneous ICH  
 Spontaneous intracerebral hemorrhage constitutes 10 % to 15% of all strokes and 
is a devastating stroke subtype.  Clinical trials of surgical interventions have failed to 
demonstrate a consistent benefit[15].  Many predictors of negative outcome have been 
consistently described in patients suffering from spontaneous ICH, including oral 
anticoagulant therapy[3, 5].  Futhermore, warfarin use has been associated with larger 
volumes of ICH on baseline imaging, subsequent ICH growth, and increased mortality[16, 
17].  Since hemorrhage expansion is an independent predictor of mortality and poor 
functional outcome, established guidelines require the prompt reversal of warfarin-
induced effects[18]. 
 
Effects on Outcome in Spontaneous ICH 
 Whether or not antiplatelet medication use at the time of spontaneous ICH 
influences hemorrhage expansion and neurologic outcome is controversial.  Several 
studies with various designs, sizes, and exclusion criteria have displayed conflicting 
results (Table 1)[7, 9, 10, 19-23].  While these studies typically report the use of any 
antiplatelets together in one research arm, aspirin users account for the vast majority of 
the subpopulation in all studies.  The efficacy of platelet transfusion as it relates to 
outcome was specifically assessed in only one study, but often not in the remainder, thus 
possibly confounding outcome comparison between the reports[24].      
The placebo arms of several randomized studies have been evaluated to determine 
if any link exists between prehospital antiplatelet use and ICH volume.  The Cerebral 
Hemorrhagic and NXY-059 Treatment trial reported no relationship between prior 
antiplatelet use and the volume of ICH on baseline CT, ICH growth, or clinical outcome 
at 90 days[23].  In a phase II trial of rFVIIa for acute ICH, treatment with the 
recombinant factor and a longer time from onset to baseline CT were related to a 
decrease in hemorrhage growth in five models of ICH growth; four of the five models 
found no relationship between antiplatelet use and ICH growth[25].  In these studies, no 
transfusion of platelets was provided to study participants.  Within these studies, at least 
80% of the antiplatelet groups were taking ASA alone.  The effect of antiplatelet use on 
outcomes in other prospective and retrospective analyses ranges from non-significant to a 
2.7-fold increased 30 day mortality rate and a 7.6-fold increase in hematoma 
enlargement[7, 9, 10, 19-23].     
No study specifically addresses the effects of P2Y12 ADP receptor inhibitors on 
spontaneous ICH.  When a specific agent was specified by the study, clopidogrel and 
ticlopidine were being taken by 0 to 35.1% of the patients in the antiplatelet arms of 
studies in the literature[7, 9, 10, 19-23].  Toyoda et al.[10] reported on a series of 251 
total patients with 57 antiplatelet users prior to spontaneous ICH.  Ticlopidine was used 
secondary to the lack of availability of clopidogrel in Japan at the time.  Twelve patients 
were on ticlopidine alone and 8 were taking a combination of ticlopidine and another 
antiplatelet (35.1%).  In this series, the use of prehospital antiplatelet agents was an 
independent predictor for hematoma enlargement (p<0.01), emergent evacuation 
(p=0.021) and emergent death[10]. 
 
Reversal of Antiplatelet Agents in Spontaneous ICH 
In the setting of a spontaneous intracranial hemorrhage, attempts to “reverse” 
antiplatelet-induced effects upon platelets are the mainstay of treatment at most 
institutions[26].  However, based upon reports pertaining to mostly aspirin users with 
intracranial hemorrhage, some authors argue these actions are not clinically 
warranted[27].  While clopidogrel may have a safety profile similar to aspirin, several 
studies have demonstrated excessive bleeding in various clinical settings[28-31].  
Furthermore, a randomized study reported the combination of clopidogrel and aspirin 
provided significantly more potent inhibition of platelet function when compared to 
monotherapy with aspirin[32].  To the authors’ knowledge, no report exists dedicated to 
outcome comparison in the setting of spontaneous ICH in patients taking pre-hospital 
aspirin compared with those taking a P2Y12 inhibitor.  Given that clopidogrel-induced 
platelet dysfunction is typically more severe than aspirin; most neuro-intensivists and 
neurosurgeons continue recommend aggressive reversal of P2Y12 inhibitors in the setting 
of spontaneous ICH[26].   
 
Traumatic ICH 
     Traumatic brain injury (TBI) is responsible for more than one million hospital 
visits, roughly 200,000 hospital admissions, and 50,000 deaths in the United States 
annually[33].  Given the considerable increase in the use of antiplatelet agents for stroke 
prevention and cardiac prophylaxis, many patients taking antiplatelet agents will 
subsequently experience intracranial hemorrhage secondary to TBI.  In an attempt to 
reduce the increased morbidity and mortality associated with TBI in patients on 
antiplatelet or anticoagulant medications, some centers frequently reverse the effects of 
antiplatelet agents with platelet transfusion.  In a study of anticoagulated patients with 
traumatic ICH, rapid warfarin reversal led to a reduction in hemorrhage progression and a 
decrease in mortality (p < 0.001)[6].  However, the reversal of platelet dysfunction in 
patients with TBI on antiplatelet medications has not been fully investigated and no 
guidelines currently exist regarding this practice.  
 
Effects on Outcome in Traumatic ICH 
   The current review includes 1 prospective and 10 retrospective studies that have 
evaluated the outcomes associated with prehospital antiplatelet use in patients admitted 
for traumatic head injuries (Table 2)[8, 34-43].  Of the retrospective evaluations, 
Rozzelle, et al.[35] compared 31 subdural hematoma patients on prehospital antiplatelet 
agents with controls and found no difference in-hospital mortality, but a 2.6-fold increase 
in craniotomies for this population.  Mina, et al.[36] reported 34 patients with any TBI on 
preinjury warfarin, heparin, aspirin, NSAIDs, dipyridamole, clopidogrel, or 
pentoxifylline and found that this diverse group of patients had significantly more deaths 
when compared with controls not taking any anticoagulation or antiplatelet agents 
(p=0.006).  In another retrospective evaluation, Ohm, et al.[38] examined 90 patients 
with traumatic ICH on prehospital antiplatelets in contrast to 89 matched controls not 
receiving antiplatelets.  In-hospital mortality was 23% in the antiplatelet cohort compared 
with 8.9% in the control group (p= 0.016)[38].  Ivascu, et al.[8] evaluated 109 patients on 
various antiplatelet agents as compared with 42 control patients and discovered those on 
preinjury antiplatelets were more likely to present with a higher grade hemorrhage than 
control patients not taking any antiplatelet agents (p=0.04).  In another large retrospective 
review, 126 patients with hemorrhagic TBI were compared to controls not on any 
antiplatelet agent or anticoagulation.  No significant differences between the groups were 
noted, leading the authors to conclude that preinjury antiplatelet or anticoagulant 
pharmacotherapy did not adversely impact outcome in elderly patients with blunt 
traumatic ICH[41].   
  Few studies have isolated the type of antiplatelet agent as it relates to outcome.  In 
a prospective evaluation of the aspirin (ASA) effect upon traumatic brain injury, Spektor, 
et al.[37] reported 110 patients taking 100mg of ASA with mild or moderate head injury.  
However, traumatic intracranial hemorrhage was noted in only 27 (24.5%) patients in the 
aspirin-treated group and in 31 patients (25.6%) in the control group[37].  Thus, there 
was no statistically significant increase in the frequency or types of traumatic ICH in low-
dose ASA users.  Jones, et al.[39] attempted to evaluate the effects of clopidogrel in a 
general trauma population.  Of the 41 patients isolated, only 25 had a head injury and 
only 9 had a traumatic ICH.  While statistical reporting was lacking secondary to the 
small sample size, a higher percentage of patients in the clopidogrel group underwent 
cranial surgery, had rebleeding, and required transfusions of blood products than the 
control group, but mortality and hospital length of stay were not different than 
controls[39].  In an analysis of patients with traumatic ICH, Wong, et al.[40] reported on 
131 patients taking preinjury ASA, clopidogrel and warfarin and found that clopidogrel 
demonstrated a 14.7-fold increase in the mortality after spontaneous ICH and resulted in 
a 3-fold increase in disposition to a long-term care facility.  Though there are few studies 
that directly focus upon outcome associated with a specific antiplatelet agent, the two 
analyzing the use of clopidogrel prior to a traumatic ICH both reported worsened 
outcomes[39, 40]. 
 
Reversal of Antiplatelets in Traumatic ICH 
 Based on the majority of the studies available, it is conceivable that preinjury 
antiplatelet therapy may convert a minor traumatic ICH into a progressive ICH[11].   
However, currently available studies do not offer recommendations to clinicians on the 
use of reversal agents for patients with TBI on preinjury antiplatelet therapy.  One study 
assessed patients who received platelet transfusions compared with those who did not to 
assess outcome differences in the setting of traumatic ICH[43].  In this multi-center 
retrospective series, 166 patients with traumatic ICH received platelet transfusions, and 
162 did not.  The mortality rate for the transfused patients was 17.5%, while mortality for 
those who did not receive platelet transfusions was 16.7% (p=0.85)[43].  Unfortunately, 
statistical analysis was not reported for any specific anti-platelet agent.  Hence, though at 
first glance it may seem that, as with warfarin, reversal of antiplatelet effects with platelet 
transfusion should lead to a reduction in mortality and morbidity in the setting of a 
traumatic ICH, the only study that assessed this hypothesis did not find evidence to 
support this practice.  
 
Options for Reversal  
 The literature regarding “reversal” of prehospital aspirin therapy after acute 
intracranial hemorrhage is equivocal.  At many institutions, it is standard practice to 
recommend platelet transfusion in the setting of intracranial hemorrhage in an effort to 
stem the salicylate effect upon platelet aggregation[44].  Although there is no specific 
antidote, the aspirin effect is believed to be reversed by one platelet transfusion (1 single 
donor or 5 pooled concentrates)[26, 45].  Furthermore, other agents for reversal of the 
aspirin effect have received basic investigation.  Desmopressin seems capable of 
correcting aspirin-induced platelet dysfunction, although large clinical studies describing 
relevant outcome parameters have not been undertaken[46-48].  Altman, et al.[49] treated 
healthy volunteers with aspirin and found that recombinant factor VIIa (rFVIIIa) 
combined with other agonists was able to reverse the anti-aggregating effect of aspirin.  
No randomized study has been reported outcomes of acute ICH with reference to the 
reversal the aspirin effect.   
 Clopidogrel belongs to the class of thienopyridine derivatives, which act by 
blocking the ADP receptor on the platelet.  Like aspirin, no specific antidote exists for the 
reversal of these agents.  In an ex vivo study on healthy volunteers given aspirin and 
clopidogrel, a platelet transfusion consisting of 10 to 12.5 concentrate units successfully 
restored platelet reactivity[45].  However, given that an active metabolite of clopidogrel 
persists after cessation of the medication, some experts recommend continued platelet 
transfusion 4 or 5 days after the last dose of the medication[44].  In another ex vivo study 
of healthy volunteers treated with aspirin plus clopidogrel, rFVIIa reversed the inhibitory 
platelet effects of these agents[49].  While the clinical utility of desmopressin has not 
been assessed in the ICH population, Ranucci, et al.[50] reported the antiplatelet effects 
of clopidogrel and aspirin were partially reversed by an intravenous infusion of 
desmopressin after carotid endarterectomy.  No randomized studies have been reported to 
assess outcomes after the reversal of thienopyridines in the setting of acute ICH. 
Proposed Protocol for Reversal of Antiplatelets 
 Given the various clinical reports currently available and the absence of any 
established guidelines in the literature, the current authors’ have developed a multi-
disciplinary institutional protocol for antiplatelet reversal in the setting of an acute ICH 
(Figure 1).  The authors would like to accentuate the fact that this protocol is based 
purely upon the recommendations of a local multi-disciplinary team comprised of 
hematologists, intensivists and neurosurgeons.  Patients presenting with an intracranial 
hemorrhage on ASA alone are given 5 platelet concentrate units upon admission.  Those 
patients presenting with an acute ICH on clopidogrel with small hemorrhages and a 
neurologic exam that is able to be followed receive an initial transfusion of 10 platelet 
concentrate units.  For those patients with a severe acute ICH on clopidogrel, 10 units of 
platelets are transfused initially with 0.3µg/kg of desmopressin, and platelets are 
subsequently transfused every 12 hours for the next 48 hours.  Data regarding clinical 
outcomes is currently being accumulated.      
 
Discussion 
Effect of pharmacokinetics 
 There is a known substantial variation in patient response to antiplatelet 
medications[51].  This diversification of molecular effectiveness amongst patients may, 
in part, explain some of the conflicting outcome results seen in the retrospective reviews 
presented in Table 1 and Table 2.  Recently, Naidech et al.[52-54] reported several 
studies linking objective measures of platelet function with increased mortality, increased 
early clot growth, worse functional outcomes at 3 months and intraventricular extension 
after ICH.  These authors used two bedside optical detection systems which measured 
platelet induced aggregation inhibition due to aspirin and clopidogrel.  They determined 
that abnormal platelet activity results, not the reported use of antiplatelet medications 
were associated with these negative outcomes and posited that increasing platelet activity 
may be a more appropriate potential target to improve outcomes after ICH[53].  While 
more studies at various centers are needed to confirm these findings, these studies 
provide early evidence that restoring the platelet activity in specifically targeted patients 
directly upon admission may be of benefit. 
 
Next-generation Antiplatelet Agents 
  Potent metabolites of the thienopyridines (clopidogrel and ticlopidine) irreversibly 
inhibit the P2Y12 receptor. Thus, urgent surgical intervention in patients taking these 
agents is often problematic.  From the cardiac literature, clopidogrel treatment within 4–5 
days of a coronary artery bypass grafting procedures has been associated with increased 
blood loss, reoperation for bleeding, increased transfusion requirements, and prolonged 
intensive care unit and hospital stays[14, 29, 55].  As emergent surgery is often a 
necessity in the setting of acute coronary syndrome, two direct and reversible P2Y12 
antagonists with rapid onset of action have been developed.  These new agents, which are 
currently in Phase III trials, are attractive alternatives to the thienopyridines, especially in 
situations whereby the rapid inhibition of platelet aggregation or its quick reversal are 
required[56].  Thus, with the addition of these new P2Y12 inhibitors, physicians will be 
able to prescribe a more patient-specific antiplatelet regimen based upon individual risk-
benefit analysis. 
 
Summary of Findings 
 The data assessing the relationship between outcomes and prehospital antiplatelet 
agents in the setting of ICH is contradictory in both the trauma and the stroke literature.  
The majority of studies reveal a worsened outcome in ICH after taking ASA.  After 
clopidogrel ingestion both dedicated studies in the trauma literature noted worse 
outcomes, while the study including the highest percentage of patients taking 
thienopyridines in the spontaneous ICH literature noted worse outcomes as well when 
compared to controls[10, 39, 40].  Only one retrospective review assessed outcomes after 
platelet transfusion, the mainstay of antiplatelet reversal at many institutions.  Currently, 
a randomized trial is recruiting patients in order to determine whether platelet transfusion 
ameliorates hematoma enlargement in the setting of acute ICH[7].  At present, the 
literature contains insufficient information to establish any guidelines or treatment 
recommendations.  In light of this, the current authors have proposed a protocol for 
antiplatelet reversal in both spontaneous and traumatic acute ICH.    
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Table 1: Literature review of the effect of antiplatelet agents upon outcome in 
spontaneous ICH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 2:  Literature review of the effect of antiplatelet agents upon outcome in the setting 
of traumatic ICH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 1:  Proposed protocol for reversal of antiplatelet agents in the setting of acute 
intracranial hemorrhage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
